Modus Therapeutics Holding AB (OSTO:MODTX) Accounts Payable: kr0.94 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MODTX Modus Therapeutics Holding AB OSTO:MODTX
30 GF Score
Price kr0.37
! 1 Warning Sign
View Full Analysis

What is Modus Therapeutics Holding AB Accounts Payable?

Modus Therapeutics Holding AB OSTO:MODTX -1.85% 30 Accounts Payable is kr0.94 Mil as of Mar. 2026. GuruFocus rates OSTO:MODTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Modus Therapeutics Holding AB's Accounts Payable for the quarter that ended in Mar. 2026 was kr0.94 Mil.

Modus Therapeutics Holding AB's quarterly Accounts Payable increased from Sep. 2025 (kr1.75 Mil) to Dec. 2025 (kr2.27 Mil) but then declined from Dec. 2025 (kr2.27 Mil) to Mar. 2026 (kr0.94 Mil).

Modus Therapeutics Holding AB's annual Accounts Payable increased from Dec. 2023 (kr1.31 Mil) to Dec. 2024 (kr1.56 Mil) and increased from Dec. 2024 (kr1.56 Mil) to Dec. 2025 (kr2.27 Mil).

Modus Therapeutics Holding AB Accounts Payable Related Terms

Modus Therapeutics Holding AB Accounts Payable Historical Data

* Premium members only.

The historical data trend for Modus Therapeutics Holding AB's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Modus Therapeutics Holding AB Accounts Payable Chart

Modus Therapeutics Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 4.49 1.36 1.31 1.56 2.27

Modus Therapeutics Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 1.48 1.75 2.27 0.94
OSTO:MODTX
30GF Score
Modus Therapeutics Holding AB OSTO:MODTX
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Modus Therapeutics Holding AB Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of kr0.94 Mil mean?
Modus Therapeutics Holding AB (OSTO:MODTX) has a Accounts Payable of kr0.94 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Modus Therapeutics Holding AB and its competitors.
Is Modus Therapeutics Holding AB's Accounts Payable too high?
Modus Therapeutics Holding AB's current Accounts Payable is kr0.94 Mil. Overall, Modus Therapeutics Holding AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Modus Therapeutics Holding AB's Accounts Payable compare to VRTX and REGN?
Modus Therapeutics Holding AB's Accounts Payable of kr0.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Modus Therapeutics Holding AB and its competitors. Modus Therapeutics Holding AB's current Accounts Payable is kr0.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modus Therapeutics Holding AB stock overvalued right now?
Modus Therapeutics Holding AB (OSTO:MODTX) has a current Accounts Payable of kr0.94 Mil. The current Accounts Payable is kr0.94 Mil. Modus Therapeutics Holding AB's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Modus Therapeutics Holding AB (OSTO:MODTX), the current Accounts Payable is kr0.94 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Modus Therapeutics Holding AB Business Description

Address Olof Palmes gata 29 IV, Stockholm, SWE, 111 22
Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a potential treatment for unmet medical needs. Its research focuses on conditions involving severe systemic inflammation, including sepsis and septic shock, severe malaria, and other related disorders, as well as anemia associated with chronic inflammatory conditions such as kidney disease.
30GF Score

Get the complete analysis for OSTO:MODTX

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.37
Price